|
시장보고서
상품코드
2024544
호흡기세포융합바이러스 진단 시장 보고서 : 제품별, 최종 용도별, 지역별(2026-2034년)Respiratory Syncytial Virus Diagnostics Market Report by Product, End Use, and Region 2026-2034 |
||||||
세계의 호흡기세포융합바이러스(RSV) 진단 시장 규모는 2025년에 11억 7,260만 달러에 달했습니다. 향후에 대해 IMARC Group은 2026-2034년에 CAGR 7.27%로 성장하며, 2034년까지 22억 4,670만 달러에 달할 것으로 예측하고 있습니다.
호흡기세포융합바이러스(RSV)는 폐와 기도에 감염되는 바이러스성 질환으로 천식, 입원, 폐렴, 재발성 감염, 중이염, 심지어 사망에까지 이를 수 있습니다. 혈액검사, 흉부 엑스레이 검사, 분비물 면봉 검사, 펄스 옥시미터 등을 통해 폐의 염증, 백혈구(WBC) 수, 혈중 산소 농도 등의 징후를 확인하여 진단할 수 있습니다. RSV에 대한 일반적인 치료법으로는 일반의약품(OTC), 정맥주사(IV), 가습 산소, 인공호흡기, 흡입형 기관지확장제 등이 있습니다.
호흡기세포융합바이러스(RSV) 진단 시장 동향
RSV 감염은 2세 이하의 영유아가 심각한 호흡기 증상을 일으키기 쉽기 때문에 신생아기에 더 심각한 경과를 보일 수 있습니다. 이러한 점과 더불어 부모들의 소아 의료에 대한 관심이 높아지면서 시장 성장을 촉진하는 중요한 요인 중 하나로 작용하고 있습니다. 또한 조기 진단 후 높은 생존율과 진단법의 손쉬운 이용 가능성도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이 외에도 의료 인프라의 개선과 입원 중인 영아 치료에 대한 유리한 보험 환급 정책도 시장 성장에 기여하고 있습니다. 또한 생명공학 및 나노테크놀러지과 같은 첨단 기술의 등장으로 웨스턴블롯, 효소면역측정법(ELISA), 직접면역형광법, 실시간 중합효소연쇄반응(PCR) 등 RSV에 대한 최신 검출 시스템 개발이 촉진되고 있습니다. 이 외에도 많은 국가의 규제 당국은 새로운 치료법 개발을 위한 연구개발(R&D) 프로젝트에 자금을 지원하고 있습니다. 시장을 촉진할 것으로 예상되는 다른 요인으로는 임상 백신 검사 증가, 체외 진단에 대한 수요 증가, 소아 폐렴 발생률 증가, 분자 진단 방법의 보급 확대 등이 있습니다.
이 보고서에서 답변하는 주요 질문
- 세계의 호흡기세포융합바이러스(RSV) 진단 시장은 지금까지 어떻게 성장하며왔으며, 향후 수년간 어떻게 변화하는가?
- COVID-19는 세계의 호흡기세포융합바이러스(RSV) 진단 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 제품별로 보면 시장 내역은?
- 최종 용도별 시장 현황은?
- 이 산업의 밸류체인에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계의 호흡기세포융합바이러스(RSV) 진단 시장의 구조는 무엇이며, 주요 진출 업체는 어디인가?
- 산업내 경쟁의 강도는 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 호흡기세포융합바이러스 진단 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 최종 용도별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porters Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSA 26.05.18The global respiratory syncytial virus (RSV) diagnostics market size reached USD 1,172.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 2,246.7 Million by 2034, exhibiting a growth rate (CAGR) of 7.27% during 2026-2034.
Respiratory syncytial virus (RSV) is a viral infection of the lungs and respiratory tract, which can cause asthma, hospitalization, pneumonia, repeated infections, middle ear infection, and death. It can be diagnosed using blood tests, chest x-rays, a swab of secretions, and pulse oximetry by checking for signs like lung inflammation, white blood cell (WBC) count, and oxygen levels in the blood. Some of the commonly available treatment options for RSV are over-the-counter (OTC) medications, intravenous (IV) fluids, humidified oxygen, mechanical ventilation, and inhaled bronchodilators.
RESPIRATORY SYNCYTIAL VIRUS (RSV) DIAGNOSTICS MARKET TRENDS:
RSV infection can be more serious during the neonatal period as children under two years of age tend to develop severe respiratory symptoms. This, in confluence with the rising focus of parents on child medical care, represents one of the crucial factors fostering the growth of the market. Moreover, the high survival rates after early diagnosis and the easy availability of diagnostic modalities act as other growth-inducing factors. Apart from this, the improving healthcare infrastructure and favorable reimbursement policies for the treatment of hospitalized infants are also contributing to market growth. Furthermore, the advent of advanced techniques like bio- and nanotechnology is facilitating the development of modern detection systems for RSV, such as western blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). Besides this, governing agencies of numerous countries are funding research and development (R&D) projects for the development of new therapeutics. Other factors projected to drive the market are the growing number of clinical vaccine trials, the escalating demand for in-vitro diagnostics, rising incidences of childhood pneumonia and the increasing adoption of molecular diagnostics.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Direct Fluorescent Antibody (DFA) Method
- Rapid Antigen Diagnostic Test (RADTs)
- Molecular Diagnostics
- Chromatographic Immunoassay
- Diagnostic Imaging
- Gel Microdroplets
- Flow Cytometry
- Others
Breakup by End Use:
- Hospitals and Clinics
- Laboratory
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Coris BioConcept, DiaSorin Molecular LLC (DiaSorin Inc), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics Incorporated, Quidel Corporation and Thermo Fisher Scientific Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global respiratory syncytial virus (RSV) diagnostics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global respiratory syncytial virus (RSV) diagnostics market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global respiratory syncytial virus (RSV) diagnostics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Respiratory Syncytial Virus (RSV) Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Direct Fluorescent Antibody (DFA) Method
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Rapid Antigen Diagnostic Test (RADTs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Molecular Diagnostics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Chromatographic Immunoassay
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Diagnostic Imaging
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Gel Microdroplets
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Flow Cytometry
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by End Use
- 7.1 Hospitals and Clinics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Laboratory
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Becton, Dickinson and Company
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 bioMerieux SA
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Bio-Rad Laboratories Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Coris BioConcept
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 DiaSorin Molecular LLC (DiaSorin Inc)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 F. Hoffmann-La Roche AG
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 SWOT Analysis
- 13.3.8 Merck KGaA
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Quest Diagnostics Incorporated
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Quidel Corporation
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Thermo Fisher Scientific Inc.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.11.4 SWOT Analysis
- 13.3.1 Abbott Laboratories
